

Application of a novel cloud-based platform for kinetic model identification in pharmaceutical processes

Emmanuel Agunloye^a, Panagiotis Petsagkourakis^a, Muhammad Yusuf^b, Ricardo Labes^b, Thomas Chamberlain^b, Frans L. Muller^b, Richard A. Bourne^b, and Federico Galvanin^{a*}

^aDepartment of Chemical Engineering, University College London, Torrington Place, London, WC1E 7JE, United Kingdom

^bSchool of Chemical and Process Engineering, University of Leeds, Leeds, LS2 9JT, United Kingdom

*corresponding author: f.galvanin@ucl.ac.uk



? Introduction and Motivation

- Recently, the pharmaceutical industry reported alarming rates of drug recalls and expanding time to launch a new drug for relying on outdated technologies [1].
- The industry consequently embraced a new framework to incorporate industry 4.0 technologies into drug manufacturing to guarantee quality and accelerate commercialization [1].
- In accordance, this work presents pharmaceutical applications of a novel cloud-based platform driven by optimal experimental design software deployed from University College London to remotely control experimentation in a smart flow reactor system situated at University of Leeds [2].

Methodology

- Fig. 1 shows the cloud-based platform with the cloud anchoring data and design of experiments (DoEs) communication between the LabBot reactor hardware and the Python-coded SimBot software [2].
- The optimal experimental design software integrates model-free and model-based DoE techniques.




Fig. 1: The novel cloud-based platform

Simbot modelling and optimisation structure

- Differential and algebraic equations (DAEs):

$$\mathbf{f}(\dot{\mathbf{x}}(\tau), \mathbf{x}(\tau), \mathbf{u}(\tau), \boldsymbol{\theta}, \tau) = \mathbf{0} \quad \text{Eq. 1}$$

$$\hat{\mathbf{y}}(t) = \mathbf{g}(\mathbf{x}(\tau)); \mathbf{x}(0) = \mathbf{x}_0 \quad \text{Eq. 2}$$

$$\boldsymbol{\phi} = [\mathbf{u}^T, \tau, \mathbf{x}_0^T]^T; \mathbf{x}(\tau) \in \mathcal{X} \quad \text{Eq. 3}$$

Eq. 1 describes the reactor DAEs model initialised and measured using Eq. 2 within the design space described by Eq. 3.

- Modelling objectives [3]:

- Parameter estimation (Module 3 for maximizing the log-likelihood function):

$$\psi_{PE} = \max_{\boldsymbol{\phi} \in \boldsymbol{\Phi}} (-1) \left[\log(2\pi)^{N_s N_y} + \sum_{s=1}^{N_s} \sum_{k=1}^{N_y} \log \det \mathbf{V}_y + (\hat{\mathbf{y}} - \mathbf{y})^T \mathbf{V}_y^{-1} (\hat{\mathbf{y}} - \mathbf{y}) \right] \quad \text{Eq. 4}$$

- Model-based DoE for model discrimination (for maximizing divergence among rival models):

$$\psi_{MD} = \max_{\boldsymbol{\phi} \in \boldsymbol{\Phi}} \left\{ (\mathbf{y}^1 - \mathbf{y}^2)^T \left[(\mathbf{V}_y^1)^{-1} + (\mathbf{V}_y^2)^{-1} \right] (\mathbf{y}^1 - \mathbf{y}^2) \right\} \quad \text{Eq. 5}$$

- Model-based DoE for model parameter precision (for maximizing a scalar measure of the Fisher information matrix):

$$\psi_{PP} = \max_{\boldsymbol{\phi} \in \boldsymbol{\Phi}} \psi \left[\sum_{r=1}^{r=n} \sum_{s=1}^{s=n} \sigma_1^{rs} \mathbf{Q}_r^T \mathbf{Q}_s \right] \quad \text{Eq. 6}$$

$\mathbf{x}(t)$: state variable, $\hat{\mathbf{y}}(t)$: measurements, $\mathbf{u}(t)$: control variables, $\boldsymbol{\theta}$: parameters, t : time; \mathbf{y} : model expectation, N_s : sampling points; \mathbf{V} : response covariance matrix with elements σ_1^{rs} ; \mathbf{Q} : sensitivities to model parameters $\partial \mathbf{f} / \partial \boldsymbol{\theta}$; ψ : objective function; N_y : measurements

- References:
- Destro, F., Barolo, M., 2022 Inter J. Pharmaceutics, 620, 121715, ISSN 0378-5173, <https://doi.org/10.1016/j.iupharm.2022.121715>
 - Agunloye, E., Petsagkourakis, P., Yusuf, M., Labes, R., Chamberlain, T., Muller, F.L., Bourne, R.A., and Galvanin, F., (submitted)
 - Bard, Y. Academic Press 1974.
 - Boonen et al., 2012. J Ethnopharmacol., 1;142(3):563-90. doi: 10.1016/j.jep.2012.05.038.
 - Reed-Berendt et al., 2021. ACS Central Sci., 7 (4), 570-585, DOI: 10.1021/acscentsci.1c00125

Results

Case Study 1: Homogeneous amide formation

- Amides are a promising group of organic compounds for producing drugs [4].
- In the homogeneous amide formation, two mechanisms can be inferred from literature: forward-step and reversible-step.
- χ^2 lack-of-fit test integrated in the cloud-based platform (Table 1) accepted the reversible model (with 4 parameters) as the best model for the amide formation (Module 3).
- MBDoE for parameter precision (i.e., robust model performance) subsequently selected the most informative experiment that improved the reversible model predictions as shown in the results in Fig. 2 with full-factorial experimental designs for model validation (Module 5).

Table 1: Two candidate kinetic models of amide formation with their χ^2 performances

	Chemical equations	Rate equations	χ^2 test
Model 1	$RCOOR' + R''NH_2 \rightarrow RCONH_2 + R''OR'$	$r_f = k_f c_1 c_2$	$\chi^2 = 494.1$ ($\chi_{ref}^2 = 23.7$)
Model 2	$RCOOR' + R''NH_2 \rightleftharpoons RCONH_2 + R''OR'$	$r_f = k_f c_1 c_2$ $r_b = k_b c_3 c_4$	$\chi^2 = 7.29 \cdot 10^{-9}$ ($\chi_{ref}^2 = 21.03$)
$c_1 = RCOOR'; c_2 = R''NH_2; c_3 = RCONH_2; c_4 = R''OR'$			




Fig. 2: A: Parameter precision, B: Fisher information map, C: Design space showing the locations of preliminary (blue), MBDoE (red) and validation (black) experiments; and D: Model validation parity plot. PDoE: Preliminary DoE; CBDDoE: Control-bound DoE.

Case Study 2: Heterogeneous hydrogen borrowing

- Hydrogen borrowing is a widely used protocol in the pharmaceutical industry to diversify alcohols over several hydrogen borrowing cycles in new drug discovery [5].
- Fig. 3 shows the classical mechanistic theory for describing a hydrogen borrowing cycle [5].
- The platform via sequential parameter estimation and MBDoE for model discrimination, reduced 6 initially tested candidate kinetic models to 2 models with identifiable parameters (Table 2) and allowed to test the latter models in silico for distinguishability (Fig. 4).




Fig. 3: Classical hydrogen borrowing mechanism [4]

Table 2 χ^2 model adequacy and Fisher information analyses for the six models

Model	χ^2	χ_{ref}^2	FIM-D
1 Model 1	26.49	60.48	397.00
2 Model 2	26.48	83.68	397.36
3 Model 3	23.01	92.81	0.00
4 Model 4	23.01	101.88	0.00
5 Model 5	23.01	113.15	0.00
6 Model 6	23.02	122.11	0.00




Fig. 4: In-silico divergence region to distinguish Models 1 and 2.


Conclusions

- A novel cloud-based platform for kinetic model identification has been developed, integrating optimal experimental designs software to remotely coordinate experimentation in a smart flow reactor.
- The platform has been demonstrated in two pharmaceutical applications for autonomous model identification, a crucial tool for achieving Quality-by-Design in drug manufacturing.

Acknowledgement

This project received funding from the EPSRC with the grant name: cognitive chemical manufacturing and reference: EP/R032807/1. The support is gratefully acknowledged.

Personal Information



Sargent Centre
for Process Systems
Engineering

UCL ENGINEERING
Change the world